Israel Bans Key Immunoglobulin Drug, Creating National Shortage
This article was originally published in PharmAsia News
Executive Summary
Israelis face a massive shortage of a key drug in the aftermath of the withdrawal of Omrigam, an immunoglobulin drug developed from blood plasma